SLNSW-Microsatellite instability (MSI-H) is associated ...-TN_cdi_proquest_journals_2565287403

Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

Full title: Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

Author/creator: Noepel-Duennebacke, Stefanie, Juette, Hendrik, Schulmann, Karsten, Graeven, Ulrich, Porschen, Rainer, Stoehlmacher, Jan, Hegewisch-Becker, Susanna, Raulf, Arne, Arnold, Dirk, Reinacher-Schick, Anke, Tannapfel, Aandrea.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2565287403

Language: English

Formats: Articles

Publishers: Berlin/Heidelberg: Springer Berlin Heidelberg

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2565287403

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

    Record identifier

    TN_cdi_proquest_journals_2565287403

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2565287403

    Share

    Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2565287403

    Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

    Full title

    Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

    Author / Creator

    Noepel-Duennebacke, Stefanie ; Juette, Hendrik ; Schulmann, Karsten ; Graeven, Ulrich ; Porschen, Rainer ; Stoehlmacher, Jan ; Hegewisch-Becker, Susanna ; Raulf, Arne ; Arnold, Dirk ; Reinacher-Schick, Anke ; Tannapfel, Aandrea

    Publisher

    Berlin/Heidelberg: Springer Berlin Heidelberg

    Journal title

    Journal of cancer research and clinical oncology, 2021, Vol.147 (10), p.3063-3072

    Record Identifier

    TN_cdi_proquest_journals_2565287403

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - metabolism Bevacizumab Bevacizumab - administration & dosage Biomarkers, Tumor - analysis Cancer Research Clinical trials Clinical Trials, Phase III as Topic Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - immunology Colorectal Neoplasms - metabolism Colorectal Neoplasms - mortality DNA sequencing Female Fluorouracil - administration & dosage Follow-Up Studies Hematology Humans Immunoscore Internal Medicine Male Medicine Medicine & Public Health Metastases Metastatic colorectal cancer Microsatellite Instability Middle Aged Monoclonal antibodies Neoplasm Invasiveness Oncology Original Article – Clinical Oncology Original – Clinical Oncology Overall survival Oxaliplatin Oxaliplatin - administration & dosage PD-L1 PD-L1 protein Prognosis Randomized Controlled Trials as Topic Retrospective Studies Survival Survival Rate Targeted cancer therapy Tumors

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2565287403

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2565287403

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections